Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 2.02B +187.2% |
| Revenue (ttm) | n/a |
| Net Income | -45.61M |
| EPS | -0.32 |
| Shares Out | 141.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 896,407 |
| Open | 14.82 |
| Previous Close | 15.08 |
| Day's Range | 14.06 - 14.99 |
| 52-Week Range | 5.38 - 16.12 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 21.45 (+51.06%) |
| Earnings Date | May 5, 2026 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $21.45, which is an increase of 51.06% from the latest price.
News
Trevi Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
A differentiated therapy for chronic cough is advancing through pivotal trials in IPF and RCC, with strong efficacy and safety data, a large addressable market, and a robust financial position to support development through 2030. Key data readouts are expected in 2027–2028.
Trevi Therapeutics price target raised to $30 from $18 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Trevi Therapeutics (TRVI) to $30 from $18 and keeps a Buy rating on the shares.
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $29 from $21 and keeps a Buy rating on the shares. The company’s key opinion leader event has…
Trevi Therapeutics Transcript: Investor Day 2026
The event outlined a focused strategy to lead in chronic cough with Haduvio, advancing pivotal trials in IPF, non-IPF ILD, and RCC, supported by strong financials and patent protection. Large, underserved markets and rapid physician adoption are expected, with peak sales potential of $6B across indications.
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $18 and keeps an Overweight rating on the shares after the company provided its first quarter…
Trevi Therapeutics Earnings Call Transcript: Q1 2026
Clinical programs for IPF, non-IPF ILD, and RCC chronic cough are advancing, with strong cash reserves and extended runway into 2030. New patents strengthen IP, and key trial readouts are expected in late 2026 and 2027.
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and contin...
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse...
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics to Participate in Upcoming May Events
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphi...
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Unusually active option classes on open April 17th
Unusual total active option classes on open include: Trevi Therapeutics (TRVI), V F Corp (VFC), Fortinet (FTNT), Fluence Energy (FLNC), UBS (UBS), Churchill Capital Corp X (INFQ), Critical Metals Corp...
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
Morgan Stanley, Leerink, Cantor Fitzgerald and Stifel acted as joint book running managers for the offering.
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics announces $150M common stock offering
Trevi Therapeutics (TRVI) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the offering are being offered…
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics to Participate in Upcoming Events
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
JonesResearch analyst Debanjana Chatterjee lowered the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $25 and keeps a Buy rating on the shares. The firm updated the company’s…
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Trevi Therapeutics (TRVI) to $18 from $19 and keeps an Overweight rating on the shares. The firm updated its…
Trevi Therapeutics Earnings Call Transcript: Q4 2025
Major growth in 2025 was driven by positive clinical data and a clear FDA path for pivotal trials in chronic cough. With $188M in cash, the company is positioned to fund key trials into 2028 and expand into larger markets with high unmet need.
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
The company ended 2025 with $188.3M with expected cash runway into 2028. “Our progress in 2025 marked a major inflection point for Trevi’s growth trajectory, driven by positive Phase 2…
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough
Trevi Therapeutics options imply 6.8% move in share price post-earnings
Pre-earnings options volume in Trevi Therapeutics (TRVI) is normal with calls leading puts 1:1. Implied volatility suggests the market is anticipating a move near 6.8%, or 0c, after results are…
Trevi Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Strong Phase II results in chronic cough have set the stage for two pivotal Phase III trials, with FDA alignment on endpoints and timelines targeting NDA filing in about two and a half years. Expansion into non-IPF ILD and RCC, differentiated mechanism, and robust financial runway position the program for significant commercial impact.
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...